Quick Answer
Bone Biologics Corp reported Stockholders Equity of $5.38 million for the year ending 2025.
- Bone Biologics Corp showed an increase of +54.4% in Stockholders Equity from 2024 to 2025.
- This data is from Bone Biologics Corp's annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2010 to 2025 (24 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$8.53 million | Q2 2018: -$9.46 million | Q3 2018: -$7.17 million | Q4 2018: -$8.60 million | Q1 2019: -$9.97 million | Q2 2019: -$10.86 million | Q3 2019: -$11.38 million | Q1 2020: -$12.46 million | Q2 2020: -$12.84 million | Q3 2020: -$13.24 million | Q1 2021: -$14.12 million | Q2 2021: -$14.62 million | Q3 2021: -$15.13 million | Q1 2022: $6.04 million | Q2 2022: $5.59 million | Q3 2022: $4.40 million | Q1 2023: $2.77 million | Q2 2023: $5.69 million | Q3 2023: $3.79 million | Q1 2024: $3.67 million | Q2 2024: $2.91 million | Q3 2024: $3.79 million | Q1 2025: $2.91 million | Q2 2025: $6.60 million | Q3 2025: $6.02 million.
- Over the full 24 years of available data (2010 to 2025), Bone Biologics Corp's Stockholders Equity has grown by 22,461.7%.
- Historical annual values: Fiscal year 2025: $5.38 million | Fiscal year 2024: $3.48 million | Fiscal year 2023: $2.91 million | Fiscal year 2022: $5.95 million | Fiscal year 2021: $6.58 million | Fiscal year 2020: -$13.69 million | Fiscal year 2019: -$11.87 million | Fiscal year 2018: -$8.60 million | Fiscal year 2017: -$8.40 million | Fiscal year 2017: -$10.18 million | Fiscal year 2017: -$9.68 million | Fiscal year 2017: -$7.85 million | Fiscal year 2016: -$8.36 million | Fiscal year 2016: -$6.96 million | Fiscal year 2016: -$5.38 million | Fiscal year 2016: -$3.23 million | Fiscal year 2015: -$4.20 million | Fiscal year 2014: -$3.70 million | Fiscal year 2013: -$5.61 million | Fiscal year 2013: -$39.8 thousand | Fiscal year 2012: -$4.68 million | Fiscal year 2012: -$34.6 thousand | Fiscal year 2011: -$29.0 thousand | Fiscal year 2010: -$24.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: